Tirzepatide

Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.

Rodriguez PJ, et al. · JAMA internal medicine · 2024

Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.

Look M, et al. · Diabetes, obesity & metabolism · 2025

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

Aronne LJ, et al. · The New England journal of medicine · 2025

Tirzepatide for Obesity Treatment and Diabetes Prevention.

Jastreboff AM, et al. · The New England journal of medicine · 2025

Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.

Zhao L, et al. · JAMA · 2024

Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

Loomba R, et al. · The New England journal of medicine · 2024

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).

Wilson L, et al. · Diabetes, obesity & metabolism · 2026

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

Rosenstock J, et al. · Lancet (London, England) · 2021

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.

Zeng Q, et al. · Frontiers in endocrinology · 2023

Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes.

Chuang MH, et al. · JAMA network open · 2024

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.

Willard FS, et al. · JCI insight · 2020

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.

Ludvik B, et al. · Lancet (London, England) · 2021